PowerShares Dynamic Pharmaceuticals ETF News

The slew of Q1 results have led to mixed trading in pharma ETFs over the past month.

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,

The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Stocks came crashing on the first day of the New Year in apprehension of the outcome of the Georgia run-off elections.

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

News that a Pfizer and BioNTech vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial has instilled more optimism in the markets.

Chances of a dividend congress caused a superb rally in Wall Street the day after election.